Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab in Mantle Cell Lymphoma Post CAR T-cell Therapy
NCT07453095Phase 2Recruiting
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in mantle cell lymphoma (MCL), sponsored by Fondazione Italiana Linfomi. Started Jun 2026; status: recruiting.
02
Drugs
glofitamab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07453095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07453095.